Pembrolizumab Approved for Advanced Esophageal Squamous Cell Carcinoma

Pembrolizumab (Keytruda®, Merck) has been approved by the FDA for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus (ESCC) with tumors expressing a programmed death ligand-1 (PD-L1) combined positive score (CPS) of at least 10 and with disease progression following one or more previous systemic treatments. The approval was based on the Keynote-181 (NCT02559687) and Keynote-180 (NCT02564263) clinical trials. Keynote-181 enrolled 628 patients with recu...
Continue reading

HSCT: Improving Communication Between the Transplant Center and the Oncologist With Miguel-Angel Perales, MD

While hematopoietic stem cell transplant (HSCT) offers a curative treatment option for many patients, oncologists face unique challenges, including the underutilization of transplant, the need for improved communication between the transplant center and the community oncologist, and the implementation of CAR T-cell therapy. In this interview with i3 Health, Miguel-Angel Perales, MD, addresses these challenges and discusses the importance of clinical trial enrollment and innovative programs that ...
Continue reading

Opposite of Sweet: High-Fructose Corn Syrup Promotes Colon Cancer Growth

Researchers have discovered that two sweeteners used in soft drinks—high-fructose corn syrup and sucrose—encourage colon cancer growth in mice. For the experiment, results of which were published in Science, the investigators administered a daily dose of high-fructose corn syrup, an amount equivalent to one soda for humans, to mice who had been genetically engineered to develop colon cancer. A control group of mice, also genetically engineered to develop colon cancer, was not fed high-fructose c...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.